Neurology & Immunology

We have a long heritage in researching, supporting and advocating for people with neurological and immunological diseases, in and out of the laboratory.

Share

leaders in Multiple Sclerosis

EMD Serono's experience and scientific discoveries in MS date back more than 20 years. We have an ongoing commitment to improving the entire patient experience. To this end, we offer delivery devices for our therapeutic products as well as comprehensive patient education resources.

It is the people living with MS or those who will be diagnosed with MS, their caregivers and healthcare providers who have been our catalyst and inspiration to continue innovating, collaborating and advocating.

Get closer to MS

The science of MS is still under construction

We’re breaking down the science behind the condition to reconstruct a new understanding of MS that may build a better future for patients.

Beyond Medications

Comprehensive Care Resources

We know that caring for someone with MS goes beyond providing medicines, which is why we work to support people with educational programs and financial resources to address concerns about treatment, adherence and access. We aim to integrate our top minds in research and development with insights from people with MS and healthcare providers to address real-world concerns for people living with this condition.

For more than 15 years, MS LifeLines® has provided valuable education, information about our treatment and financial assistance programs for eligible people to address concerns about their treatment, adherence and access.

Curiosity Drives Our Future

With our history in neurology and leadership as a science-driven organization, we are deepening our commitment to people with neurological and immunological diseases by researching and innovating new therapeutic options that can make a real difference in their lives.

The development and discovery of innovative treatments for MS remains a top focus for our scientists. Our pipeline has potential to impact treatment across multiple immunological conditions, including MS, rheumatoid arthritis and systemic lupus erythematosus.

We are also investigating new treatments for immunological conditions such as psoriasis and systemic sclerosis with interstitial lung disease.

Our Pipeline

Browse the programs in our pipeline to see what we're currently working on by phase, therapeutic area and compound type.

Our Products

Our research and development led to the introduction of
Rebif® (interferon beta-1a), a disease-modifying therapy for people living with MS. Even today, after being available for more than 15 years, Rebif remains an important therapy for people with relapsing forms of MS.
Rebif (interferon beta-1a) is used to treat relapsing forms of MS to decrease the frequency of relapses and delay the occurrence of some of the physical disability that is common in people with MS.

Important Safety Information

Rebif can cause serious side effects including the following: behavioral health problems including depression and suicidal thoughts, serious allergic and skin reactions, injection site skin damage, liver problems or worsening of liver problems including liver failure. Symptoms may include changes in urine, stool, and skin color, tiredness, confusion, and bleeding. Rebif can also cause low red and white blood cell and platelet counts. Symptoms may include infections, seizures, problems with bleeding and bruising.

For complete product details, please refer to the full Prescribing Information and Medication Guide for full disclosure.

EMD Serono is the biopharmaceutical business of Merck KGaA, Darmstadt, Germany.
This site contains information that is intended for residents of the United States only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy.
This site contains information that is intended for US residents only. Canadian residents should consult the EMD Serono Canada Inc. website at www.emdserono.ca for information on products and services approved in Canada.

Cookie Disclaimer

This website uses 'cookies' to give you the best, most relevant experience. Using this website means you’re Ok with this. You can change which cookies are set at any time - and find out more about themin our cookie policy.
Cookie Policy

Redirect

Site Exit Disclaimer

You are now leaving the website of EMD Serono, the biopharma business of Merck KGaA, Darmstadt, Germany. This link will either lead to a different website maintained by EMD Serono/its global business, or a different website/resource maintained by 3rd parties.

If you are visiting a 3rd party website, we have no control over the content and are not responsible for and make no representation as to the accuracy or any other aspect of such resource or the privacy practices of such 3rd party. Providing links to a 3rd party website does not constitute EMD Serono’s endorsement of such website or the information or products presented on such website.

Share Disclaimer

By sharing this content, you are consenting to share your data to this social media provider. More information are available in our Privacy Statement.